Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $29.73, denoting a +0.61% change from the preceding trading day.
Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...
Zacks Investment Research on MSN13h
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With ZealandNovo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
Here is how the Barron’s Roundtable members’ picks performed. Find investment ideas for your portfolio with the latest stock picks from Barron’s below. These picks are the product of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback